Trial
NCT05276492
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Chicago
Collaborators
—
Condition
Prostate Cancer
Intervention
Abiraterone Oral Tablet
Why stopped
Closed by PI due to not meeting primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-03